Mosapride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mosapride
Accession Number
DB11675
Type
Small Molecule
Groups
Investigational
Description

Mosapride is under investigation for the treatment and prevention of Postoperative Ileus and Gastric Peroral Endoscopic Pyloromyotomy (G-POEM). Mosapride has been investigated for the treatment and diagnostic of Constipation, Type 2 Diabetes, Functional Dyspepsia, Functional Constipation, and Epigastric Pain Syndrome, among others.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Mosapride CitrateMF497J489P112885-42-4HUZTYZBFZKRPFG-UHFFFAOYSA-N
International/Other Brands
Gasmotin (Dainippon Pharmaceutical Co., Ltd.)
Categories
UNII
I8MFJ1C0BY
CAS number
112885-41-3
Weight
Average: 421.9
Monoisotopic: 421.1568475
Chemical Formula
C21H25ClFN3O3
InChI Key
YPELFRMCRYSPKZ-UHFFFAOYSA-N
InChI
InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
IUPAC Name
4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide
SMILES
CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Mosapride is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Mosapride is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Mosapride.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when Mosapride is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of serotonin syndrome can be increased when 3,4-Methylenedioxyamphetamine is combined with Mosapride.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Mosapride.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Mosapride is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Mosapride.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of serotonin syndrome can be increased when Mosapride is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Mosapride.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
119584
PubChem Substance
347828043
ChemSpider
106780
BindingDB
94630
ChEBI
94373
ChEMBL
CHEMBL60889
Wikipedia
Mosapride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentGastritis1
1CompletedTreatmentHealthy Volunteers1
1RecruitingTreatmentFunctional Constipation / Functional Diarrhea1
1Unknown StatusTreatmentFunctional Constipation1
1, 2Not Yet RecruitingTreatmentFunctional Dyspepsia / Traditional Chinese Medicine1
3CompletedDiagnosticForeign Body Left During Endoscopic Examination1
3CompletedPreventionPrevention of Postoperative Ileus1
3CompletedTreatmentFunctional Dyspepsia1
3CompletedTreatmentOccasional Constipation1
3RecruitingTreatmentFunctional Dyspepsia3
3TerminatedTreatmentConstipation-predominant Irritable Bowel Syndrome (IBS-C)1
3Unknown StatusPreventionNausea / Vomiting1
4Active Not RecruitingOtherColorectal Polyps1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedTreatmentEpigastric Pain Syndrome / Functional Dyspepsia / Post Prandial Distress Syndrome1
4Not Yet RecruitingTreatmentChronic Constipation / Constipated Irritable Bowel Syndrome / Healthy Volunteers1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4RecruitingPreventionPostoperative paralytic ileus1
4Unknown StatusTreatmentDiabetic Gastroparesis1
Not AvailableNot Yet RecruitingNot AvailableGastro-esophageal Reflux Disease (GERD)1
Not AvailableNot Yet RecruitingTreatmentGastro-esophageal Reflux Disease (GERD)1
Not AvailableRecruitingTreatmentGastric Peroral Endoscopic Pyloromyotomy (G-POEM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0218 mg/mLALOGPS
logP3.14ALOGPS
logP2.75ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.46ChemAxon
pKa (Strongest Basic)5.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area76.82 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity112.34 m3·mol-1ChemAxon
Polarizability43.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-0910400000-7b60d0e3ee1a9a5d92c9

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Aminophenyl ethers
Direct Parent
Aminophenyl ethers
Alternative Parents
Aniline and substituted anilines / Phenylmethylamines / Phenoxy compounds / Benzylamines / Alkyl aryl ethers / Aralkylamines / Chlorobenzenes / Fluorobenzenes / Aryl chlorides / Aryl fluorides
show 12 more
Substituents
Aminophenyl ether / Phenoxy compound / Phenylmethylamine / Benzylamine / Aniline or substituted anilines / Alkyl aryl ether / Halobenzene / Fluorobenzene / Chlorobenzene / Aralkylamine
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:38 / Updated on November 02, 2018 09:01